Overview

18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer

Status:
Recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This is an interventional, single group assignment, prospective nonrandomized, open label Phase 2 trial designed to evaluate 18F-DCFPyL PET imaging in men diagnosed with prostate cancer with increasing prostate-specific antigen (PSA) levels.
Phase:
Phase 2
Details
Lead Sponsor:
Ashok Muthukrishnan
Collaborator:
Progenics Pharmaceuticals, Inc.